biostudies-literatureUnknown16(1)Srivastava SThis study received funding from ADM. The funder had the following involvement with the study: study design, writing and reviewing of the manuscript. MN, VV and RD are employed by ADMTo determine the efficacy of the probiotic <i>Bifidobacterium longum</i> CECT 7347 (ES1) and postbiotic heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in improving symptom severity in adults with diarrhea-predominant irritable bowel syndrome (IBS-D), a randomised, double-blind, placebo-controlled trial with 200 participants split into three groups was carried out. Two capsules of either ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to placebo. Secondary outcome measures were stool consistency, quality of life, abdominal pain severity and anxiety scores. Safety parameters and adverse events were also monitored. The change in IBS-SSSGut microbes2338322https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028008biostudies-literatureA randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live <i>Bifidobacterium longum</i> CECT 7347 (ES1) and heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.PMC11028008Srivastava SBasak UJadon PSPandit ANaghibi MDay RDargad RRKhanna SVijayakumar VParihar RPatel JKumar SfalseA randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live <i>Bifidobacterium longum</i> CECT 7347 (ES1) and heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.To determine the efficacy of the probiotic <i>Bifidobacterium longum</i> CECT 7347 (ES1) and postbiotic heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in improving symptom severity in adults with diarrhea-predominant irritable bowel syndrome (IBS-D), a randomised, double-blind, placebo-controlled trial with 200 participants split into three groups was carried out. Two capsules of either ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to placebo. Secondary outcome measures were stool consistency, quality of life, abdominal pain severity and anxiety scores. Safety parameters and adverse events were also monitored. The change in IBS-SSS2024-01-01T00:00:00Z2024 Jan-Dec2026-05-29T12:23:30.945Z2026-05-19T03:07:31.793ZS-EPMC110280083863001510.1080/19490976.2024.2338322